TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05006599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
Study: NCT05524454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel CBCT Imaging
Description: One or two CBCT images are acquired on the novel CBCT imaging system.
Study: NCT05911633

Intervention type: DEVICE
Group type: OTHER
Intervention: BioPearl™
Description: TACE
Study: NCT05820087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics Edison System
Description: Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
Study: NCT05030155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 300 mg/month subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 300 mg/month subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide/azathioprine
Description: Patients with FFS≥1 will receive cyclophosphamide then azathioprine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with FFS=0 will receive placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients with FFS=0 will receive placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with FFS=0 will receive placebo
Study: NCT05123352

Intervention type: OTHER
Intervention: collection of biological samples and clinical data
Description: blood and feces samples

Intervention type: OTHER
Intervention: collection of biological samples and clinical data
Description: blood and feces samples
Study: NCT06180135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TURKISH COFFEE DRINK
Description: TURKISH COFFEE DRINK

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FENNEL TEA DRINK
Description: FENNEL TEA DRINK
Study: NCT05740124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: slip recovery training
Description: Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: alternative balance training
Description: Participants practice standing and walking under varied sensory conditions.
Study: NCT06558344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1569912
Description: Placebo matching BI 1569912
Study: NCT06365125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO
Description: Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCHECKUP TO GO
Description: Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging boosters
Description: Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
Study: NCT05205304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D'Oxyva
Description: The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
Study: NCT05318469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilmab
Description: Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
Study: NCT05056129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-controlled digital game (SCDG)
Description: The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensor Only
Description: Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
Study: NCT04671667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT
Study: NCT05137080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline
Study: NCT04929028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anoscopy
Description: Undergo anoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anoscopy
Description: Undergo anoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo digital rectal exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo digital rectal exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT06462729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDGraft
Description: LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDGraft
Description: LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Bone
Description: Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)
Study: NCT05785039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study: NCT05341973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
Study: NCT04929028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI or PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT or PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy
Description: Undergo proctoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy
Description: Undergo proctoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study: NCT05682885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Bypass Supermicrosurgery
Description: Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
Study: NCT04924660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027
Description: TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study: NCT06641570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Exercise Program
Description: This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Program
Description: This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land-based Exercise Program
Description: This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.
Study: NCT06644378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3866288
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3866288
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3866288
Description: Administered IV.
Study: NCT06171659

Intervention type: DRUG
Intervention: FDG radiotracer
Description: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

Intervention type: DRUG
Intervention: FDG radiotracer
Description: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

Intervention type: DRUG
Intervention: FDG radiotracer
Description: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

Intervention type: DRUG
Intervention: FDG radiotracer
Description: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

Intervention type: DEVICE
Intervention: PET/MRI
Description: positron emission tomography and magnetic resonance imaging

Intervention type: DEVICE
Intervention: PET/MRI
Description: positron emission tomography and magnetic resonance imaging

Intervention type: DEVICE
Intervention: PET/MRI
Description: positron emission tomography and magnetic resonance imaging

Intervention type: DEVICE
Intervention: PET/MRI
Description: positron emission tomography and magnetic resonance imaging

Intervention type: DEVICE
Intervention: PET/CT imaging
Description: positron emission tomography and computed tomography imaging

Intervention type: DEVICE
Intervention: PET/CT imaging
Description: positron emission tomography and computed tomography imaging

Intervention type: DEVICE
Intervention: PET/CT imaging
Description: positron emission tomography and computed tomography imaging

Intervention type: DEVICE
Intervention: PET/CT imaging
Description: positron emission tomography and computed tomography imaging
Study: NCT06322680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Main pancreatic duct and biliary duct external drainage
Description: Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Main pancreatic duct and biliary duct internal drainage
Description: Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures.
Study: NCT06576817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity circuit exercise class - Lower and upper extremity
Description: Exercises performed at high intensity effort in the circuit (8 total) will focus on both the lower extremity (4) and upper extremity (4)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity circuit exercise class - Lower extremity alone
Description: All exercises performed at high intensity effort in the circuit (8 total) will focus on the lower extremity alone
Study: NCT05058651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study: NCT05499897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasoud guided interscalene block
Description: Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: general anesthesia
Description: Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
Study: NCT06027554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone Mesylate
Description: MitoQ given 20 mg per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule taken every day for 12 weeks.